TABLE 1:

Prevalence of LE in patients with ALL treated with intrathecal MTX and CRT prophylaxis

Study	Modality	Prevalence of LE^*	Point in Therapy
Chu et al, 2003¹⁴	MR imaging	0/2 (0)	Baseline
Chu et al, 2003¹⁴	MR imaging	0/3 (0)	8 wk after diagnosis
Chu et al, 2003¹⁴	MR imaging	1/3 (33)	20 wk after diagnosis
Paakko et al, 1996¹⁰	MR imaging	0/12 (0)	End Consolidation
Ochs et al, 1983⁵	CT	5/55 (9)	Continuation
Paakko et al, 2000¹²	MR imaging	0/16 (0)	During
McIntosh et al, 1977³	CT	10/30 (33)	0.5–6 y after induction
Peylan-Ramu et al, 1978⁴	CT	5/32 (16)	3.5 y after diagnosis
Chu et al, 2003¹⁴	MR imaging	1/3 (33)	1 year after therapy
Chu et al, 2003¹⁴	MR imaging	1/2 (50)	2 y after therapy
Paakko et al, 1992⁸	MR imaging	3/16 (19)	3 y after therapy
Chu et al, 2003¹⁴	MR imaging	2/2 (100)	3 y after therapy
Brouwers and Poplack 1990⁶	CT	5/23 (22)	4 y after therapy
Ochs et al, 1991⁷	CT	8/23 (35)	6 y after therapy
Hertzberg et al, 1997¹¹	CT, MR imaging	23/41 (56)	6 y after therapy
Kingma et al, 1993⁹	MR imaging	24/35 (69)	8 y after diagnosis
Hertzberg et al, 1997¹¹	CT, MR imaging	23/38 (61)	9 y after therapy
Kingma et al, 2001¹³	MR imaging	15/24 (63)	10 y after diagnosis